Navigation Links
BioMS Medical completes patient recruitment in phase III U.S. multiple sclerosis trial
Date:8/1/2008

---------

MBP8298 (dirucotide) is a synthetic peptide that consists of 17 amino acids having a sequence identical to that of a portion of human myelin basic protein (MBP). MBP8298 (dirucotide) is being developed for the potential treatment of multiple sclerosis (MS), an autoimmune disease caused by immune attack against normal components of the central nervous system. The sequence of MBP8298 is associated with the autoimmune process in MS patients with certain immune response genes (HLA types DR2 and/or DR4); MS patients having these genes represent 65 to 75 percent of all MS patients.

The apparent mechanism of action of MBP8298 (dirucotide) is the induction or restoration of immunological tolerance with respect to ongoing immune attack as a result of high doses of peptide delivered periodically by the intravenous route. The potential benefit of MBP8298 (dirucotide) for any individual patient is therefore expected to be related to the role this peptide plays in that patient's immune system. The degree of immunomodulation achieved will depend on the relationship among the peptide, HLA molecules and T cells.

The results of phase II and long-term follow-up treatment of MS patients with MBP8298 (dirucotide), published in 2006 in the European Journal of Neurology (EJN), showed that MBP8298 (dirucotide) safely delayed median time to disease progression for five years (versus placebo) in progressive MS patients with HLA types DR2 and/or DR4. Thus, MBP8298 (dirucotide) has the potential to be used as a tailored therapy for patients genetically determined to express the appropriate HLA molecules.

About Multiple Sclerosis

------------------------

Multiple sclerosis (MS) is thought to affect as many as 2.5 million people worldwide, including approximately 75,000 in Canada, 400,000 in the United States and more than 500,000 in Europe. It is a disease that affects more women than men, with onset typically occurring between 20 and 50 year
'/>"/>

SOURCE BioMS Medical Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. BioMS Medical announces its intention to renew a normal course issuer bid
2. BioMS Medical to present at BioContact 2007
3. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
4. BioMS Medical achieves enrollment milestone in U.S. phase III multiple sclerosis trial
5. BioMS Medical announces third quarter 2007 results
6. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
7. BioMS Medicals pivotal international multiple sclerosis trial receives positive review from Data Safety Monitoring Board
8. Lilly and BioMS Medical Announce Global Licensing and Development Agreement
9. BioMS Medical to present at BIO CEO & Investor Conference
10. BioMS Medical Announces 2007 Year End Results
11. BioMS Medical to present at BioCentury Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... , September 2, 2015 ... primär auf die Forschung und Entwicklung neuartiger ... Allergien, chronisch-entzündliche Darmerkrankungen und Reizdarm konzentriert, erhält ... Zusage, dass sein neues Medikament patentiert wird. ... das Allergien bei Kindern verhindert und Entzündungen ...
(Date:9/1/2015)... 1, 2015  ContraVir Pharmaceuticals, Inc. (NASDAQ: CTRV ... commercialization of targeted antiviral therapies, announced today that it ... Annual Global Investment Conference sponsored by H.C. ... at The St. Regis Hotel in New ... Sapirstein , Chief Executive Officer, will provide an overview ...
(Date:9/1/2015)... ... 01, 2015 , ... In her thought provoking debut novel ‘ Ebola Vaccine ... future faced with an Ebola pandemic that is on the cusp of wiping out ... the world of counterterrorism, and who continues to appear in this series of books ...
(Date:9/1/2015)... 1, 2015 The Dohmen Company today ... Ph.D., MBA as Chief Science Officer (CSO) of ... created role, Dr. Floyd will lead Dohmen,s growing ... of pre-commercial and post approval outsourced services in ... communications.  Dr. Floyd brings decades of experience leading ...
Breaking Biology Technology:Das Patent von Swecure zur Verhinderung von Allergien bei Kindern wird in den USA zugelassen 2ContraVir to Present at Rodman & Renshaw 17th Annual Global Investment Conference 2Alexi Venice’s Debut Novel Takes on the Human Testing of a Vaccine for Ebola and Revenge by an Anti-Big Pharma Terrorist Group in ‘Ebola Vaccine Wars' 2Alexi Venice’s Debut Novel Takes on the Human Testing of a Vaccine for Ebola and Revenge by an Anti-Big Pharma Terrorist Group in ‘Ebola Vaccine Wars' 3Dohmen Life Science Services Appoints Eric Floyd, Ph.D. as Chief Science Officer 2Dohmen Life Science Services Appoints Eric Floyd, Ph.D. as Chief Science Officer 3
... and security guards came to the DHS Science and Technology ... their list was an emergency escape hood worthy of James ... a pound, folding to the dimensions of a DVD case, ... hood must be maintenance-free, filter nerve, blood, and blister agents, ...
... Will Host Conference Call Today at 5:00 p.m., ... ) announced today that the FDA has informed the,company ... the,160L bioreactor scale and Myozyme produced at the 2000L ... differences in the,carbohydrate structures of the molecules. Currently, Genzyme ...
... Dissolve Powder Antacid Delivers Faster Relief, ... Increased Convenience and Great Taste, PITTSBURGH, April ... integrated marketing campaign,for the new TUMS(R) QuikPak(TM), the first and ... QuikPak campaign, part of,a larger new "Bring It On" brand ...
Cached Biology Technology:Boys in the Hood 2Genzyme Provides Update on Myozyme(R) Manufacturing 2Genzyme Provides Update on Myozyme(R) Manufacturing 3Genzyme Provides Update on Myozyme(R) Manufacturing 4Genzyme Provides Update on Myozyme(R) Manufacturing 5New TUMS(R) QuikPak(TM) Campaign Offers Innovative Heartburn Relief with a Little Help from the Jetsons 2
(Date:8/24/2015)... 2015 The consulting company Frost & ... manufacturer DERMALOG and its customized solutions and products for ... of the Year Award". DERMALOG is particularly successful with a ... -Cross reference: Picture is available at AP Images ... On Thursday evening, in South Africa,s ...
(Date:8/20/2015)... Aug. 20, 2015 The wearable technology ... are active and healthy. However, wearable technology has ... environment to help improve diagnostic capabilities and therapeutic ... the Wearable Technologies Conference 2015 , where ... for wearables in healthcare.    "Over ...
(Date:8/20/2015)... 20, 2015 NXT-ID, Inc. (NASDAQ: NXTD ... focused on the growing mobile commerce market and creator ... The Smart Card Alliance and the EMV Migration Forum.  ... the Smart Card Alliance Latin America (SCALA) Chapter provides ... and thought leaders promoting adoption of smart card technology. ...
Breaking Biology News(10 mins):Frost & Sullivan Honors DERMALOG with Biometrics Prize for Achievements in Africa 2Frost & Sullivan Honors DERMALOG with Biometrics Prize for Achievements in Africa 3Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 2Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 3NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 2NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 3NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 4
... IN Traditional turfgrass management programs rely heavily ... In response to increased public scrutiny and legislation, ... but research indicates that these alternatives have not ... lawn care industry. Results of a new study ...
... as the great pandemia of the XXI century. Recent data ... suffering from overweight, of which 300 million are clinically obese. ... worrying increase, with more than 155 million children and adolescents ... Biologist Aline Jelenkovic analysed to what point corporal morphology was ...
... QUEBEC, CANADA A study in HortTechnology ... reducing solar heat radiation and temperatures during the hot ... Canadian researchers, was the first investigation into the effects ... shading method. Results showed that the technology improved greenhouse ...
Cached Biology News:Turfgrass fertility, pesticide programs compared 2The amount of adipose tissue should be taken into account in the fight against obesity 2The amount of adipose tissue should be taken into account in the fight against obesity 3New technology improves greenhouse, plant microclimates 2
The Bio-Plex Manager version 3.0 to 4.0 workstation software upgrade kit is used to upgrade existing Bio-Plex Manager version 3.0 software to version 4.0 security edition software....
... --- a cocktail of 3 siRNAs specifically ... our most popular product. The siTrio reagent ... of your target gene when used under ... and confirmation of optimal transfection with one ...
... is a competitive enzymeimmunoassay (EIA) for the ... rat serum or plasma. Corticosterone is the ... and mice, and in most non-mammalian vertebrates ... mammals produce both corticosterone and cortisol, in ...
... is a molecular screening, low melting point ... sieving. It is recommended for separation of ... such as PCR products. Micro ABgarose is ... not recommended for blotting techniques. At a ...
Biology Products: